Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Open-label Study of Nivolumab Combined With Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients With Clear Cell Advanced Renal Cell Carcinoma

Next Previous
Search
Trial Profile

A Phase 2 Open-label Study of Nivolumab Combined With Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients With Clear Cell Advanced Renal Cell Carcinoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lutetium-177-DOTA-girentuximab (Primary) ; Nivolumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms STARLITE 2

    • Most Recent Events

    • 03 Mar 2025 According to the Telix Japan media release, Eric Jonasch, MD, Professor of Medicine in the Department of Genitourinary Medical Oncology at MD Anderson Cancer Center in Houston, TX, will discuss the details of STARLITE studies of TLX250, in an investors webinar to be held on Tues Mar 11, 5.30pm
    • 13 Feb 2025 According to the Telix Japan media release, data from this study will be presented in a Poster session on February 15, 2025, at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2025) to be held in San Francisco, CA (US) from 13 - 15 February 2025.
    • 03 Feb 2025 Planned End Date changed from 1 Mar 2025 to 1 Mar 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top